Visuospatial Deficits Are Associated with Pisa Syndrome and not Camptocormia in Parkinson's Disease.
Parkinson's disease
Pisa syndrome
camptocormia
cognition
postural abnormalities
Journal
Movement disorders clinical practice
ISSN: 2330-1619
Titre abrégé: Mov Disord Clin Pract
Pays: United States
ID NLM: 101630279
Informations de publication
Date de publication:
Jan 2023
Jan 2023
Historique:
received:
28
06
2022
revised:
29
09
2022
accepted:
04
10
2022
entrez:
27
1
2023
pubmed:
28
1
2023
medline:
28
1
2023
Statut:
epublish
Résumé
Pisa syndrome (PS) and camptocormia (CC) are postural abnormalities frequently associated with Parkinson's disease (PD). Their pathophysiology remains unclear, but the role of cognitive deficits has been postulated. To identify differences in the neuropsychological functioning of patients with PD with PS or CC compared with matched patients with PD without postural abnormalities. We performed a case-control study including 57 patients with PD with PS (PS+) or CC (CC+) and 57 PD controls without postural abnormalities matched for sex, age, PD duration, phenotype, and stage. Patients were divided into four groups: PS+ (n = 32), PS+ controls (PS-, n = 32), CC+ (n = 25), and CC+ controls (CC-, n = 25). We compared PS+ versus PS- and CC+ versus CC- using a neuropsychological battery assessing memory, attention, executive functions, visuospatial abilities, and language. Subjective visual vertical (SVV) perception was assessed by the Bucket test as a sign of vestibular function; the misperception of trunk position, defined as a mismatch between the objective versus subjective evaluation of the trunk bending angle >5°, was evaluated in PS+ and CC+. PS+ showed significantly worse visuospatial performances ( Low visuospatial performances and vestibular tone imbalance are significantly associated with PS but not with CC. These findings suggest different pathophysiology for the two main postural abnormalities associated with PD and can foster adequate therapeutic and prevention strategies.
Sections du résumé
Background
UNASSIGNED
Pisa syndrome (PS) and camptocormia (CC) are postural abnormalities frequently associated with Parkinson's disease (PD). Their pathophysiology remains unclear, but the role of cognitive deficits has been postulated.
Objectives
UNASSIGNED
To identify differences in the neuropsychological functioning of patients with PD with PS or CC compared with matched patients with PD without postural abnormalities.
Methods
UNASSIGNED
We performed a case-control study including 57 patients with PD with PS (PS+) or CC (CC+) and 57 PD controls without postural abnormalities matched for sex, age, PD duration, phenotype, and stage. Patients were divided into four groups: PS+ (n = 32), PS+ controls (PS-, n = 32), CC+ (n = 25), and CC+ controls (CC-, n = 25). We compared PS+ versus PS- and CC+ versus CC- using a neuropsychological battery assessing memory, attention, executive functions, visuospatial abilities, and language. Subjective visual vertical (SVV) perception was assessed by the Bucket test as a sign of vestibular function; the misperception of trunk position, defined as a mismatch between the objective versus subjective evaluation of the trunk bending angle >5°, was evaluated in PS+ and CC+.
Results
UNASSIGNED
PS+ showed significantly worse visuospatial performances (
Conclusions
UNASSIGNED
Low visuospatial performances and vestibular tone imbalance are significantly associated with PS but not with CC. These findings suggest different pathophysiology for the two main postural abnormalities associated with PD and can foster adequate therapeutic and prevention strategies.
Identifiants
pubmed: 36704069
doi: 10.1002/mdc3.13605
pii: MDC313605
pmc: PMC9847315
doi:
Types de publication
Journal Article
Langues
eng
Pagination
64-73Informations de copyright
© 2022 International Parkinson and Movement Disorder Society.
Références
Neurology. 2015 Nov 17;85(20):1769-79
pubmed: 26491088
Mov Disord. 2010 Nov 15;25(15):2649-53
pubmed: 21069833
Neurology. 2000 Dec 12;55(11):1621-6
pubmed: 11113214
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Neurology. 2009 May 12;72(19):1689-92
pubmed: 19433743
PLoS One. 2017 Jul 10;12(7):e0181210
pubmed: 28700731
Lancet Neurol. 2011 Jun;10(6):538-49
pubmed: 21514890
Front Neurol. 2020 Mar 31;11:207
pubmed: 32296383
Parkinsonism Relat Disord. 2007 Feb;13(1):22-8
pubmed: 16931104
Lancet Neurol. 2016 Sep;15(10):1063-74
pubmed: 27571158
Mov Disord. 2013 May;28(5):668-70
pubmed: 23408503
Dan Med Bull. 1987 Apr;34 Suppl 4:1-24
pubmed: 3595217
Brain. 2011 Jul;134(Pt 7):2074-84
pubmed: 21666262
Neurobiol Aging. 2022 Jan;109:31-42
pubmed: 34649002
Parkinsonism Relat Disord. 2019 May;62:231-235
pubmed: 30442481
Parkinsonism Relat Disord. 2018 Jul;52:69-75
pubmed: 29606604
Parkinsonism Relat Disord. 2018 Jul;52:1-5
pubmed: 29907329
Parkinsonism Relat Disord. 2014 Nov;20(11):1140-4
pubmed: 25175601
Acta Neurol Scand. 2016 Aug;134(2):101-7
pubmed: 26427765
Sci Rep. 2018 Jan 29;8(1):1804
pubmed: 29379091
Mov Disord. 2008 Nov 15;23(15):2129-70
pubmed: 19025984
Mov Disord. 2015 Oct;30(12):1591-601
pubmed: 26474316
Parkinsons Dis. 2015;2015:462143
pubmed: 26351615
J Am Geriatr Soc. 2005 Apr;53(4):695-9
pubmed: 15817019
Front Neurol. 2019 May 31;10:577
pubmed: 31214112
CNS Drugs. 2002;16(3):165-74
pubmed: 11888337
Arch Neurol. 1978 Jun;35(6):364-7
pubmed: 655909
Neurology. 2010 Sep 21;75(12):1062-9
pubmed: 20855849
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
J Neural Transm (Vienna). 2022 Aug;129(8):1001-1009
pubmed: 35753016